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Abstract
Background: To assess changes in the pattern of Invasive Meningococcal Disease (IMD) in Italy
after the introduction of conjugate menC vaccine in the National Vaccine Plan 2005–2007 and to
provide information for developing timely and appropriate public health interventions, analyses of
microbiological features of isolates and clinical characteristics of patients have been carried out. In
Italy, the number of serogroup C meningococci fell progressively following the introduction of the
MenC conjugate vaccine, recommended by the Italian Ministry of Health but implemented
according to different regional strategies.
Methods:  IMD cases from January 2005 through July 2008 reported to the National
Meningococcal Surveillance System were considered for this study. Serogrouping and sero/
subtyping were performed on 179 serogroup C strains received at the National Reference
Laboratory of the Istituto Superiore di Sanità. Antibiotic susceptibility testing was possible for 157
isolates. MLST (Multilocus sequence typing), porA VRs (Variable Region) typing, PFGE (Pulsed Field
Gel Electrophoresis), VNTR (Variable Number Tandem Repeats) analyses were performed on all
C:2a and C:2b meningococci (n = 147), following standard procedures.
Results: In 2005 and 2008, IMD showed an incidence of 0.5 and 0.3 per 100,000 inhabitants,
respectively. While the incidence due to serogroup B remained stable, IMD incidence due to
serogroup C has decreased since 2006. In particular, the decrease was significant among infants.
C:2a and C:2b were the main serotypes, all C:2a strains belonged to ST-11 clonal complex and all
C:2b to ST-8/A4. Clinical manifestations and outcome of infections underlined more severe disease
caused by C:2a isolates. Two clusters due to C:2a/ST-11 meningococci were reported in the North
of Italy in December 2007 and July 2008, respectively, with a high rate of septicaemia and fatal
outcome.
Conclusion:  Public health surveillance of serogroup C invasive meningococcal disease and
microbiological/molecular characterization of the isolates requires particular attention, since the
hyper-invasive ST-11 predominantly affected adolescents and young adults for whom
meningococcal vaccination was not recommended in the 2005–2007 National Vaccine Plan.
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Background
The epidemiology of meningococcal disease following
vaccination campaigns and its evolution over time has
been extensively reported [1-5]. In countries where
meningococcal vaccines are routinely used, studies on
changes in the bacterial population, in terms of capsular
switching, and/or molecular characterization, have been
carried out in order to assess the eventual impact of vacci-
nation not only on transmission but also on carriage [4].
A new epidemiological pattern of Invasive Meningococcal
Disease (IMD) has been observed over the last few years
in Italy, a country with a low incidence of the disease
(range 0.3–0.5/100,000). In particular, cases due to sero-
group C Neisseria meningitidis reported to the National
Surveillance System at the Istituto Superiore di Sanità fell
progressively from 54% (115/212) in 2005 to 36% (53/
146) in 2008 http://www.simi.iss.it. This reduction could
be explained as a consequence of increasing vaccination
coverage especially in those regions (17 of 21) that
adopted the 2005–2007 National Vaccine Plan in which
the conjugate MenC vaccination was recommended. In
particular, all infants in the first year of life and individu-
als who present with splenic dysfunction or immunodefi-
ciency are considered for vaccination [6]. However, the
vaccine coverage is uneven since the health system is
decentralised and the Italian regions are entitled to imple-
ment different meningococcal vaccination policies
according to local epidemiology and priorities. This heter-
ogeneous use of the vaccine together with the occurrence
of two outbreaks due to serogroup C meningococci with a
high rate of fatal septicaemia [7] led us to assess the
genetic characteristics of invasive serogroup C meningo-
cocci circulating in the country.
One-hundred and seventy nine serogroup C meningo-
cocci collected from invasive disease from January 2005
through July 2008 were characterised using a variety of
molecular techniques.
Methods
Bacterial strains and phenotypic characterization
Within the National Meningococcal Surveillance System,
established in 1994, the NRL received 83% (476/574) of
N. meningitidis strains isolated by local hospital laborato-
ries throughout the country from January 2005 through
July 2008.
All the received strains were subcultured to confirm the
serogroup by slide agglutination with commercial antis-
era (Remel Europe, Ltd, UK). Serotypes and serosubtypes
were determined by standard whole-cell ELISA with mon-
oclonal antibodies (purchased from NIBSC, UK).
Susceptibilities to penicillin G, rifampicin, ciprofloxacin
and ceftriaxone were determined by Etest method
(bioMérieux, Italy), according to the manufacturer's
instructions.
The breakpoints were those recommended by the Euro-
pean Monitoring Group for Meningococci (EMGM), [8]
In particular, the resistant, intermediate and susceptible
breakpoints were: penicillin MIC ≥ 1 mg/L, MIC > 0.06
mg/L to MIC < 1 mg/L, and MIC ≤ 0.06 mg/L; rifampicin
MIC ≥ 2 mg/L, MIC = 1 mg/L and ≤ 0.5 mg/l; ciprofloxacin
MIC ≥ 0.12 mg/L, MIC = 0.06 mg/L and MIC ≤ 0.03 mg/
L. For ceftriaxone, MIC ≤ 0.06 mg/l indicates susceptibil-
ity.
penA gene sequence analysis
penA gene sequence analysis was performed exclusively on
penicillin intermediate serogroup C strains (n = 100) to
determine specific alleles. DNAs were extracted by using
the QIAamp DNA minikit (Qiagen, Germany) according
to the manufacturer's instructions. The penA gene was
amplified and sequenced using primers and conditions
described by Zhang et al. [9]; the amplicon of 402 bp, cor-
responding to the amino acid residues 441 to 574 of the
transpeptidase domain of the PBP2 protein, was purified
and sequenced to identify the corresponding penA allele
using the database available at the http://neisseria.org
website [10].
Molecular analyses
Molecular characterization by MLST (Multilocus sequence
typing), porA VRs (Variable Region) typing, PFGE (Pulsed
Field Gel Electrophoresis), VNTR (Variable Number Tan-
dem Repeats) analyses, were performed on C:2a and C:2b
meningococci isolated in the study period (n = 147).
MLST of seven genes (abcZ, adk, aroE, fumC, gdh, pdhC,
pgm) was performed as described by Maiden et al. [11].
Primers, determination of sequence alleles and designa-
tion of sequence types were those described on the MLST
website http://neisseria.org/nm/typing/mlstdb/. Variable
regions (VR) 1 and 2 were submitted to the N. meningitidis
PorA variable regions database http://neisseria.org/nm/
typing/pora, whereas the VR3 corresponded to those indi-
cated by Mölling et al. [12].
PFGE was performed as already described [13]. Briefly, the
bacterial DNAs were digested with 30 U of the restriction
endonuclease  NheI (NewEngland, Biolabs, USA) over-
night at 37°C.
The CHEF-MAPPER II apparatus (Bio-Rad, USA) was used
with the following parameters: voltage of 6 V/cm, pulse
time of 0.05s to 30s, run time of 24 h. Lambda ladder
PFGE marker (New England, Biolabs, USA) was used as aBMC Infectious Diseases 2009, 9:135 http://www.biomedcentral.com/1471-2334/9/135
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molecular size standard. The gel was stained with 2 mg/
mL ethidium bromide, photographed under UV light and
digitized with Gel Doc 2000 system apparatus (Bio-Rad,
USA). The method applied for VNTR has been reported
elsewhere [14]. In brief, four VNTRs (VNTR01, VNTR02,
VNTR06, VNTR08) were analyzed for their genetic poly-
morphisms. The annealing temperatures for the four PCRs
were 59°C, 57°C, 63°C and 57°C for VNTR01, -02, -06
and -08, respectively. Five μl of mixed PCR products were
electrophoresed on a 2% SeaKem ME agarose gel (Cam-
brex Bio Science, USA). Gels were stained with ethidium
bromide and photographed under UV illumination.
The PFGE and VNTR gel photographs were analyzed using
Bionumerics software (v4.61, Applied Maths, Belgium)
and dendrograms were constructed by using the Dice
coefficient of similarity with the unweighted-pair group
method with arithmetic averages. The position tolerance
and the optimization were set to 2.5% and 1. 5%, respec-
tively for PFGE; and both were 1.00% for VNTR. PFGE
patterns that were <85% similar were considered differ-
ent.
Statistical methods
All data were managed and analysed with Epi-Info version
3.3.2. The Chi-square test was used to calculate the differ-
ences in serogroup C IMD incidence over time. A p-value
of < 0.05 was considered to be statistically significant.
Ethics
This study did not require approval from an Ethics com-
mittee. Data of patients were handled according to the pri-
vacy laws in force in Italy. The Istituto Superiore di Sanità
(ISS) is the leading technical and scientific public body of
the Italian National Health Service and is under the super-
vision of the Italian Ministry of Employment, Health and
Social Policies.
Results
Bacterial strains and clinical data of IMD
Trends in IMD incidence in Italy from 1995 to 2008 are
shown in Figure 1. The incidence of serogroup B remained
stable while the incidence of serogroup C started to
decrease in 2005
Table 1 shows serogroup B and C IMD incidence in 2004
and 2007 in different age groups. IMD incidence due to
serogroup C decreased significantly (p  < 0.05) among
infants and children aged 0 to 4 years, with an incidence
of 0.5 per 100,000 inhabitants in 2007 vs. 1.7 in 2004
(Table 1).
Annual incidence of serogroup B and C invasive meningococcal disease in Italy, 1995–2008 (cases per 100,000 inhabitants) Figure 1
Annual incidence of serogroup B and C invasive meningococcal disease in Italy, 1995–2008 (cases per 100,000 
inhabitants).
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From January 2005 through July 2008, 476 meningococci
were received by the NRL, of which 179 serogroup C
strains from patients with IMD. Serogroup C was predom-
inant in 2005: 54% (97/195), then the proportion
decreased to 26% (28/106) in 2006 (p < 0.05) and
remained low in the 0–4 year age-group but increased in
the other age groups overall: 33% (18/55) in 2007 and
46% (23/50) in the first seven months of 2008.
Analysis of serogroup C serotypes showed a considerable
change: C:2a increased from 15% (15/97) in 2005 to 48%
(13/27) in 2008, a trend which was inversely paralleled by
a decrease of C:2b from 70% (67/97) to 30% (8/27) in the
same period, (p < 0.05).
The clinical presentation of invasive meningococcal C dis-
ease was reported for 88% (157/179) of cases; outcome
was known for 81% (145/179) and underlined more
severe diseases caused by C:2a isolates, with an over two-
fold increase in septicaemia from 28% (4/14) in 2005 to
70% (9/13) in 2007. Septicaemia cases due to C:2b
remained stable: 45% (25/55) and 33% (2/6), respec-
tively Fatal cases due to C:2a meningococci increased
from 7% (1/14) to 55% (6/11), p < 0.05.
The serogroup C serosubtypes P1.5, P1.5,2, P1.2 were the
most frequently found.
penA gene analysis
A high proportion of serogroup C strains (65%, 100/157)
showed decreased susceptibility to penicillin (PenI), and
82% (82/100) of these were phenotype C:2b. The penA
sequence analysis revealed the presence of three main
alleles: penA3, and penA9 for C:2a and penA12 for C:2b.
All the examined strains were fully susceptible to
rifampicin, ciprofloxacin and ceftriaxone.
Molecular analyses
Table 2 summarizes the molecular characterisation of
serogroup C isolates. MLST grouped all C:2a isolates in
the ST-11/ET-37 complex and all the C:2b isolates in the
ST-8 complex/Cluster A4. Among the 49 C:2a strains
examined, 5 PorA genotypes were detected: 5, 2, 36-2; 5-
1, 10-8, 36-2; 7-2, 13-1, 36-2; 5, 2-1, 36-2; 5, 10-4, 36-2.
Among the 98 C:2b strains, a lower variability was found,
in particular 2 PorA genotypes has been detected: 5, 2, 36-
2 and 5, 2-1, 36-2.
Fifteen PFGE patterns were found (Figure 2): twelve
among C:2a/ST-11 strains of which three were the most
frequent: pattern A (22 isolates), pattern A2 (7 isolates),
and pattern H (8 isolates). Patterns from A to G refer to
strains with a genetic similarity >85%.
A higher genetic relatedness was found among C:2b/ST-8
strains. Three patterns have been identified: pattern M in
90 strains which differed for only 1 band from pattern
M1, found in 5 strains, and from pattern N, found in 3.
As already observed in PFGE, the results of the VNTR anal-
ysis also showed fewer patterns among C:2b/ST-8 isolates
(data not shown) than those observed among C:2a/ST-11
meningococci. In figure 3, the 28 VNTR patterns of the 49
C:2a/ST-11 strains analyzed are shown. VNTR confirmed
the similarity observed with the PFGE patterns of the C:2a
strains responsible for the two clusters which occurred in
December 2007 and in July 2008, respectively, in the
North of Italy. In particular, seven isolates belonging to
the first cluster (region Veneto) were characterized by the
Table 1: Invasive meningococcal disease incidence in Italy in 2004 and 2007
Age (years) * Incidence * Incidence due to serogroup B * Incidence due to serogroup C
2004 2007 2004 2007 2004 2007
0–4 4.2 2 0.9 1.1 1.7 0.5 (p < 0.05)
15–24 1 0.7 0.3 0.3 0.2 0.2
25–99 0.2 0.1 0.05 0.04 0.04 0.02
All ages 0.6 0.3 0.1 0.3 0.2 0.06 (p < 0.05)
* reported rates per 100,000 population
Table 2: Molecular analyses of serogroup C meningococci circulating in Italy from January 2005 through July 2008
Serogroup/serotype ST/clonal complex porA VR genotypes PFGE patterns penA alleles Total N°
C:2a ST-11/ET-37 5, 2, 36-2; 5-1, 10-8, 36-2; 7-2, 13-1, 36-2; 5, 2-1, 
36-2; 5, 10-4, 36-2
A-L A3, A9 49
C:2b ST-8/A4 5, 2, 36-2; 5, 2-1, 36-2 M-N A12 98BMC Infectious Diseases 2009, 9:135 http://www.biomedcentral.com/1471-2334/9/135
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PFGE pattern A, the most frequently found among C:2a/
ST-11 strains; whereas, the three isolates belonging to the
second cluster (region Lombardy) were characterized by
pattern A2. Two different VNTR patterns characterized
strains from each cluster and they were different from all
the others found in ST-11 complex isolates circulating in
Italy in the same period.
Discussion
Several countries have documented the effectiveness of
meningococcal conjugate C vaccines; in particular, vacci-
nation campaigns in the UK, Greece and Spain triggered a
rapid decrease in cases of serogroup C disease [3,5,15].
However, there is also evidence that in the absence of vac-
cination disease incidence may fall as naturally acquired
immunity rises [16,17] but this is not a rapid process
[2,18].
The serogroup C isolates responsible for numerous epi-
demics and outbreaks in the United States, Canada and
Europe, since the early 1990s, mainly belonged to the ST-
11 complex. Despite low carriage rates, ST-11 meningo-
cocci continue to be associated with sporadic outbreaks
worldwide [4]. These hyper-invasive strains require mas-
sive public health investigations and interventions due to
the high mortality among cases [19-21].
In Italy, serogroup C meningococcal conjugate vaccine,
available since 2002, was recommended in the 2005–
2007 National Vaccine Plan; this Plan was adopted in 17
of the 21 Italian regions. Of the 17 Italian regions, nine
included vaccination free of charge for all infants, whereas
vaccine at reduced cost was available for infants in six
additional regions [6]. In particular, all infants in the first
year of life and individuals who present with splenic dys-
function or immunodeficiency were considered for vacci-
nation.
Notification of IMD in Italy is mandatory since 1990 and
incidence is historically low (range 0.3–0.5 per 100,000
inhabitants). In Europe, as reported by official sources
such as the European Union Invasive Bacterial Infections
Surveillance Network http://www.euibis.org/documents/
2006_meningo.pdf and the European Centre for Disease
Control http://ecdc.europa.eu/en/publications/Pages/
Surveillance_Reports.aspx, notification rates vary widely
between countries, ranging from 0.25 to 4.4 per 100, 000.
These numbers reflect real differences in incidence, but
also differences between surveillance systems.
In Italy, incidence rates vary and are highest in the North
and lowest in the South. Factors such as climate or popu-
lation density may contribute to these differences. The
NRL receives an average of 80% of all strains isolated
Dendrogram of similarity obtained with Dice coefficients and arithmetic averages (UPGMA) clustering method using BioNu- merics software (version 3.5) showing the relatedness of representative Pulsed Field Gel Electrophoresis patterns of Nhe I- digested DNAs of 147 C:2a and C:2b meningococci Figure 2
Dendrogram of similarity obtained with Dice coefficients and arithmetic averages (UPGMA) clustering 
method using BioNumerics software (version 3.5) showing the relatedness of representative Pulsed Field Gel 
Electrophoresis patterns of Nhe I-digested DNAs of 147 C:2a and C:2b meningococci. Patterns that were <85% 
similar (see scale in the upper left corner) were considered different.
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VNTR patterns among meningococcal C:2a isolates recovered from locally related isolates (Veneto and Lombardy cluster  strains) in Italy Figure 3
VNTR patterns among meningococcal C:2a isolates recovered from locally related isolates (Veneto and Lom-
bardy cluster strains) in Italy. On the right, phenotypes and PFGE patterns are reported.
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annually in the country which provides a highly repre-
sentative pattern of IMD in Italy.
Although the population dynamics of meningococcal dis-
ease are characterized by serogroup B and C historically
undergoing cyclic patterns, the decrease in serogroup C in
a specific age group (infants under 5 years of age) may be
associated with menC vaccination. In addition, the major-
ity of serogroup C meningococci circulating during 2008
(data not shown) among non vaccinated people are
strains of the hypervirulent C:2a/ST-11 complex (48%),
which has replaced the previously predominant C:2b/ST-
8 clone (30% in 2005). These strains are hyper-endemic
and are responsible for an increased number of fatal cases
of septicaemia and for two clusters of cases in adults in the
North of Italy [7]. PFGE results showed a higher degree of
clonality among C/ST-8 strains compared with C/ST-11
strains, similar to previously published work [22,23].
With regard to the two clusters, strains with identical phe-
notypes and belonging to ST-11 complex, showed two dif-
ferent profiles by PFGE and VNTR, each unique for its
respective cluster and different from all the others found
in ST-11 complex isolates circulating in Italy in the same
period.
Previous studies demonstrated that conjugate vaccines
not only protect vaccinees but also reduce the carriage and
the transmission among non vaccinated people [1]. This
was observed especially among ST-11 strains after mass
vaccination campaigns. In Italy, vaccine coverage is influ-
enced by the different regional policies and in the absence
of widespread immunisation among infants, children and
adolescents, herd effect among the population is very
likely low compared to other European Countries and
may have allowed the expansion and spread of specific
hyper-virulent clones of meningococci.
Conclusion
Serogroup C invasive meningococcal disease needs to be
carefully monitored by characterizing the isolates since
hyper-virulent ST-11 meningococci are currently circulat-
ing in adolescents and young adults. This information
may be useful for eventual amendments to the current
vaccination policies. Moreover, the waning of effective-
ness of infant-only scheduled vaccination will be a focal
point for future evaluation.
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